{
  "id": "cad-rads-reporting-f06fce",
  "title": "CAD-RADS 2.0 - Reporting Text (Tables 10 & 11)",
  "source": "cad-rads-reporting.html",
  "blocks": [
    {
      "type": "paragraph",
      "text": "Sources: cad-rads/ryct (7).webp (Table 10) and cad-rads/ryct (8).webp (Table 11). Footnotes a/b retained."
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Stable chest pain (Table 10)"
    },
    {
      "type": "table",
      "columns": [
        "CAD-RADS",
        "Plaque burden",
        "Recommendations"
      ],
      "rows": [
        [
          "CAD RADS 0",
          "N/A",
          "- Reassurance. Consider non-atherosclerotic causes of symptoms."
        ],
        [
          "CAD RADS 1/2",
          "P1",
          "- Consider non-atherosclerotic causes of symptoms.\n- Consider risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 1/2",
          "P2",
          "- Consider non-atherosclerotic causes of symptoms.\n- Risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 1/2",
          "P3/P4",
          "- Consider non-atherosclerotic causes of symptoms.\n- Aggressive risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 3",
          "P1/P2/P3/P4",
          "- Consider CT-FFR, CTP or stress testing.\n- Aggressive risk factor modification and preventive pharmacotherapy.\n- Other treatments (including anti-anginal therapy) should be considered per guideline directed care.\n- If I+: Consider ICA, especially if frequent symptoms persist after guideline-directed medical therapy."
        ],
        [
          "CAD RADS 4",
          "P1/P2/P3/P4",
          "- Consider ICAa or functionalb assessment.\n- Aggressive risk factor modification and preventive pharmacotherapy.\n- Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care."
        ],
        [
          "CAD RADS 5",
          "P1/P2/P3/P4",
          "- Consider ICAa, functionalb, and/or viability assessment.\n- Aggressive risk factor modification and preventive pharmacotherapy.\n- Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care."
        ]
      ],
      "uniform": true,
      "cellWidth": 200,
      "cellHeight": 140,
      "maxLines": 6
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Acute chest pain (Table 11)"
    },
    {
      "type": "table",
      "columns": [
        "CAD-RADS",
        "Plaque burden",
        "Recommendations"
      ],
      "rows": [
        [
          "CAD RADS 0",
          "N/A",
          "- Reassurance. No further evaluation of ACS is required.\n- If Tn (+) consider other sources of increased troponin."
        ],
        [
          "CAD RADS 1",
          "P1/P2",
          "- No further evaluation of ACS is required.\n- If Tn (+) consider other sources of increased troponin.\n- Referral for outpatient follow-up for risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 1",
          "P3/P4",
          "- No further evaluation of ACS is required.\n- If Tn (+) consider other sources of increased troponin.\n- Referral for outpatient follow-up for aggressive risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 2",
          "P1/P2",
          "- If clinical suspicion of ACS is high, Tn (+) or high risk plaque (HRP) features, consider hospital admission with cardiology consultation.\n- If Tn (+) consider other sources of increased troponin.\n- Referral for outpatient follow-up for risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 2",
          "P3/P4",
          "- If clinical suspicion of ACS is high, Tn (+) or high risk plaque (HRP) features, consider hospital admission with cardiology consultation.\n- If Tn (+) consider other sources of increased troponin.\n- Referral for outpatient follow-up for aggressive risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 3",
          "P1/P2/P3/P4",
          "- Consider hospital admission with cardiology consultation.\n- Consider CT-FFR, CTP or stress testing.\n- Preventive management, including aggressive preventive pharmacotherapy. Other treatments (including anti-anginal therapy) should be considered per guideline directed care.\n- If I+: Consider ICA."
        ],
        [
          "CAD RADS 4A",
          "P1/P2/P3/P4",
          "- Hospital admission with cardiology consultation.\n- Consider ICAa or functional assessmentb.\n- Preventive management, including aggressive preventive pharmacotherapy. Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care."
        ],
        [
          "CAD RADS 4B",
          "P1/P2/P3/P4",
          "- Hospital admission with cardiology consultation.\n- ICA is recommended.\n- Preventive management, including aggressive preventive pharmacotherapy. Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care."
        ],
        [
          "CAD RADS 5",
          "P1/P2/P3/P4",
          "- Hospital admission with cardiology consultation.\n- Expedited ICA and revascularization if suspected acute occlusion.\n- Preventive management, including aggressive preventive pharmacotherapy. Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care."
        ]
      ],
      "uniform": true,
      "cellWidth": 200,
      "cellHeight": 140,
      "maxLines": 6
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Footnotes"
    },
    {
      "type": "list",
      "items": [
        "a) ICA may be favored if high-grade stenosis (>90%), high-risk plaque features or I+ (lesion-specific ischemia on CT-FFR or perfusion defects by CTP) or concordant ischemia by other stress tests and a candidate for revascularization. Benefit of revascularization should be reserved for persistent symptoms despite optimal medical therapy.",
        "b) Functional assessment includes CT-FFR, CTP, stress testing (ETT, stress echocardiogram, SPECT, PET, Cardiac MRI) or invasive FFR."
      ]
    }
  ]
}
